针对三阴性乳腺癌SPECT显像的间皮素特异性配体的临床前评估
本研究对两种抗间皮素单域抗体衍生的显像剂99mTc-A1和99mTc-C6进行放射性标记和临床前评估,在体外及三阴性乳腺癌细胞株HCC70(间皮素阳性)和MDA-MB-231(间皮素阴性)异种移植小鼠模型中评价其性能。结果显示99mTc-A1对间皮素的亲和力高于99mTc-C6,且在HCC70肿瘤中的摄取显著高于MDA-MB-231肿瘤和99mTc-C6,SPECT成功识别间皮素阳性肿瘤,99mTc-A1因特性更优被选为最适合进一步临床转化的工具。
要点
- 99mTc-A1对间皮素的亲和力较99mTc-C6高2.4倍(解离常数43.9±4.0 vs 107±16 nM,P<0.05)。
- 99mTc-A1在HCC70肿瘤中的摄取较MDA-MB-231肿瘤高5倍,较99mTc-C6高1.5倍(2.34%±0.36% vs 0.48%±0.18%和1.56%±0.43%,P<0.01)。
- SPECT使用99mTc-A1和99mTc-C6成功识别间皮素阳性肿瘤,99mTc-A1被选为最适合进一步临床转化的工具。
核心结论
- SPECT使用99mTc-A1和99mTc-C6成功识别间皮素阳性肿瘤;考虑其更优特性,99mTc-A1被选为最适合进一步临床转化的工具。
研究设计与样本
- 研究对A1和C6进行99mTc放射性标记,并在体外重组蛋白和细胞上以及三阴性乳腺癌细胞株HCC70(间皮素阳性)和MDA-MB-231(间皮素阴性)异种移植小鼠模型中进行体内评价。
主要发现
- 99mTc-A1和99mTc-C6在体外均以高亲和力结合间皮素,99mTc-A1亲和力较99mTc-C6高2.4倍(解离常数43.9±4.0 vs 107±16 nM,P<0.05)。
- 99mTc-A1和99mTc-C6在小鼠血液中2小时体内稳定性>80%,在人血液中6小时离体稳定性>90%。
- 99mTc-A1在HCC70肿瘤中的摄取(注射剂量百分比)较MDA-MB-231肿瘤高5倍,较99mTc-C6高1.5倍(2.34%±0.36% vs 0.48%±0.18%和1.56%±0.43%,P<0.01),并导致肿瘤/背景比值升高。
- 体内竞争实验证明99mTc-A1在HCC70肿瘤中摄取的特异性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mesothelin is a cell-surface glycoprotein restricted to mesothelial cells overexpressed in several types of cancer, including triple-negative breast cancer not responding to trastuzumab or hormone-based therapies. Mesothelin-targeting therapies are currently being developed. However, the identification of patients potentially eligible for such a therapeutic strategy remains challenging. The objective of this study was to perform the radiolabeling and preclinical evaluation of 99mTc-A1 and 99mTc-C6, two antimesothelin single-domain antibody (sdAb)-derived imaging agents. Methods: A1 and C6 were radiolabeled with 99mTc and evaluated in vitro on recombinant protein and cells, as well as in vivo in xenograft mouse models of the triple-negative breast cancer cell lines HCC70 (mesothelin-positive) and MDA-MB-231 (mesothelin-negative). Results: Both 99mTc-A1 and 99mTc-C6 bound mesothelin with high affinity in vitro, with 99mTc-A1 affinity being 2.4-fold higher than that of 99mTc-C6 (dissociation constant, 43.9 ± 4.0 vs. 107 ± 16 nM, P < 0.05). 99mTc-A1 and 99mTc-C6 remained stable in vivo in murine blood (>80% at 2 h) and ex vivo in human blood (>90% at 6 h). In vivo 99mTc-A1 uptake (percentage injected dose) in HCC70 tumors was 5-fold higher than in MDA-MB-231 tumors and 1.5-fold higher than that of 99mTc-C6 (2.34% ± 0.36% vs. 0.48% ± 0.18% and 1.56% ± 0.43%, respectively, P < 0.01) and resulted in elevated tumor-to-background ratios. In vivo competition experiments demonstrated the specificity of 99mTc-A1 uptake in HCC70 tumors. Conclusion: Mesothelin-positive tumors were successfully identified by SPECT using 99mTc-A1 and 99mTc-C6. Considering its superior characteristics, 99mTc-A1 was selected as the most suitable tool for further clinical translation.
引用
- Montemagno C, Bacot S, Ahmadi M, et al. Preclinical Evaluation of Mesothelin-Specific Ligands for SPECT Imaging of Triple-Negative Breast Cancer. J Nucl Med. 2018. PMID: 29572256. doi:10.2967/jnumed.117.203489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。